|
US7014998B2
(en)
|
2000-09-30 |
2006-03-21 |
Yale University |
Screening immunomodulatory agents by CTLA-4 upregulation
|
|
US20050069538A1
(en)
*
|
2003-09-18 |
2005-03-31 |
Gregorio Aversa |
Therapeutic binding molecules
|
|
GB0103389D0
(en)
*
|
2001-02-12 |
2001-03-28 |
Novartis Ag |
Organic compounds
|
|
AU2002351204B2
(en)
*
|
2001-12-03 |
2008-07-10 |
Abgenix, Inc. |
Anti-CD45RB antibodies for use in treating autoimmune disease and transplant rejection
|
|
US20050069549A1
(en)
|
2002-01-14 |
2005-03-31 |
William Herman |
Targeted ligands
|
|
WO2003061695A1
(en)
*
|
2002-01-17 |
2003-07-31 |
Amgen Inc. |
Methods of regulating cytokine receptor signaling
|
|
AU2003279657A1
(en)
*
|
2002-07-01 |
2004-01-19 |
Savient Pharmaceuticals, Inc. |
Compositions and methods for therapeutic treatment
|
|
US20040146503A1
(en)
*
|
2002-08-28 |
2004-07-29 |
Tesi Raymond J. |
Methods and compositions for inducing stable immune tolerance
|
|
US20040047858A1
(en)
*
|
2002-09-11 |
2004-03-11 |
Blumberg Richard S. |
Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
|
|
WO2005018668A1
(en)
*
|
2003-08-25 |
2005-03-03 |
Pangenetics B.V. |
Method of inducing immune tolerance
|
|
HRP20100334T1
(hr)
*
|
2003-09-18 |
2010-07-31 |
Novartis Ag |
Terapeutska humanizirana antitijela protiv cd45-izoforma
|
|
WO2007087453A2
(en)
*
|
2006-01-27 |
2007-08-02 |
Cellerant Therapeutics, Inc. |
Compositions and methods for treating haematological proliferative disorders
|
|
EP2029729A2
(en)
*
|
2006-05-31 |
2009-03-04 |
Genzyme Corporation |
Methods of using anti-thymocyte globulin and related agents
|
|
ES2526548T3
(es)
|
2006-08-18 |
2015-01-13 |
Argos Therapeutics, Inc. |
Uso de CD83 en terapias de combinación
|
|
MX2009002893A
(es)
|
2006-09-18 |
2009-07-10 |
Raptor Pharmaceutical Inc |
Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
|
|
US9045556B2
(en)
|
2007-02-07 |
2015-06-02 |
Nec Corporation |
Therapeutic agent for cancer
|
|
WO2013021784A1
(ja)
*
|
2011-08-10 |
2013-02-14 |
ナパジェン ファーマ，インコーポレテッド |
免疫寛容誘導剤
|
|
US20120077778A1
(en)
|
2010-09-29 |
2012-03-29 |
Andrea Bourdelais |
Ladder-Frame Polyether Conjugates
|
|
ES2653639T3
(es)
|
2011-02-28 |
2018-02-08 |
Napajen Pharma, Inc. |
Complejo ácido nucleico-polisacárido
|
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
EP3174902B1
(en)
|
2014-08-01 |
2019-04-17 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
An anti-cd45rc antibody for use as drug
|
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
|
EP3355937A4
(en)
|
2015-09-28 |
2019-04-17 |
Regents of the University of Minnesota |
CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AS THERAPEUTIC INTERVENTIONS AT AUTO AND ALLO IMMUNITY
|
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
|
CN109641051A
(zh)
|
2016-06-17 |
2019-04-16 |
美真达治疗公司 |
用于耗尽细胞的组合物和方法
|
|
BR112018076306A2
(pt)
|
2016-06-17 |
2019-03-26 |
Magenta Therapeutics, Inc. |
composições e métodos para a supressão de células cd117+
|
|
CA3042683A1
(en)
|
2016-11-07 |
2018-05-11 |
Coimmune, Inc. |
Bispecific antibodies that modulate tlr-4 signaling and uses thereof
|
|
MX395639B
(es)
|
2017-01-20 |
2025-03-25 |
Heidelberg Pharma Res Gmbh |
Composiciones y métodos para el agotamiento de células cd137+.
|
|
EP3514541A1
(de)
*
|
2018-01-17 |
2019-07-24 |
Siemens Healthcare Diagnostics Products GmbH |
Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors
|
|
CA3128518A1
(en)
*
|
2019-02-01 |
2020-08-06 |
Actinium Pharmaceuticals, Inc. |
Molecules and their derivatives directed against cd45
|
|
CN111707833A
(zh)
*
|
2020-06-19 |
2020-09-25 |
徐州医科大学 |
小鼠血管内外淋巴细胞识别的方法及其应用
|
|
WO2022140388A1
(en)
|
2020-12-21 |
2022-06-30 |
Allogene Therapeutics, Inc. |
Protease-activating cd45-gate car
|
|
US20240101673A1
(en)
|
2021-02-03 |
2024-03-28 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
WO2022196719A1
(ja)
|
2021-03-17 |
2022-09-22 |
第一三共株式会社 |
抗アセチルコリン受容体自己抗体に対するキメラ受容体をコードする遺伝子
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
WO2023201339A1
(en)
|
2022-04-15 |
2023-10-19 |
Kyverna Therapeutics, Inc. |
Methods and compositions for treating autoimmune disease
|
|
US20240261405A1
(en)
|
2022-06-08 |
2024-08-08 |
Kyverna Therapeutics, Inc. |
Methods and compositions for treating autoimmune disease
|
|
CN120554513B
(zh)
*
|
2025-07-28 |
2025-11-21 |
杭州华大生命科学研究院 |
一种抗cd45抗体及其应用
|